The chief executive of the biotech behind the first Covid-19 vaccine has said a new formulation is likely to be needed by the middle of next year to protect against the virus as it mutates.
Ugur Sahin, chief executive of BioNTech, told the Financial Times that as time passes, mutations will emerge that can evade the body’s immune defences. “This year [a different vaccine] is completely unneeded. But by mid next year, it could be a different situation,” he predicted.
A partnership between the German biotech and US pharmaceutical company Pfizer brought the first Covid-19 vaccine to market. It was also the first vaccine based on mRNA technology to win regulatory approval, and has been the world’s best-selling drug this year.
您已阅读28%（730字），剩余72%（1904字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。